sec filing - novogen yale uni joint venture , page-29

I would have to be the worst person to ask that question neg, every time I think the news is good and the share price will go up, it does the exact opposite, go figure?

But I do like the way they are keeping us informed, I have great faith in the direction they are heading.

Eyeinthesky, there will be more to come no doubt, is this the part that you mean where you reckon there is more to come?
"This is a large program that Novogen will need to partner in order to provide the resources and expertise to attain that goal."?


The immediate future
Now I’ll try and paint a picture of how I see the Company’s R&D program unfolding over the next 2-3 years.
?
Bringing Trilexium into and through the clinic as a stand-alone chemotherapy for glioblastoma and ovarian cancer remains a priority.
We already know it is unlikely to work in every case, but we expect it to have the potential to work in most cases, and with further studies, we hope to be able to identify responders and non-responders beforehand.
This is a program that Novogen believes it can take through with its own resources.
?
Trilexium is nothing more than an interim step on the way to identifying a family of super-benzopyran drugs capable of working against cancer stem cells across a broad
range of genotypes.
This is a large program that Novogen will need to partner in
order to provide the resources and expertise to attain that goal.
The nature of that partnership is the subject of current negotiations.
?
A second drug technology (details yet to be announced) will be undertaken by Novogen using its own resources.

We currently are conducting all of our programs on a virtual basis, with no intention at this stage of bringing the necessary expertise in-house beyond the minimum number of managers required to coordinate the effort of contractors.
This is prudent financial management, giving us the ability to switch the funding tap on and off as we see fit without being restricted by an in-house structure, and being able to call quickly on the expertise of others without having to develop it in-house.
However, our longer-term corporate goal of developing the means of delivering personalized chemo-therapy is going to require a somewhat different corporate approach.
The corporate structure and the means of funding this program are matters that are under consideration as
I write and that I expect to be unveiled in the near future.